News

Zacks Investment Research on MSN7d
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
Rocket Pharmaceuticals RCKT announced that the FDA has cleared its investigational new drug (IND) application seeking to ...
Sensorium Therapeutics Receives FDA IND Clearance for SNTX-2643, a First-in-Class, Rapid-Acting Anxiolytic
Sensorium Therapeutics, Inc. (Sensorium), a neuroscience therapeutics company inspired by nature and guided by human biology to transform mental health treatment, announced today that the U.S. Food ...
The Manila Times1d
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug ...
Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric ca ...
Morningstar25d
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of ... - Morningstar
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma Provided by PR Newswire Jun ...
SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V
SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical ...
Investing.com India14h
Longeveron stock soars after FDA approves IND for heart failure treatment
Investing.com -- Longeveron Inc. (NASDAQ: LGVN) stock surged 23% after the U.S. Food and Drug Administration approved the company’s Investigational New Drug (IND) application for laromestrocel, a ...
The Bakersfield Californian13d
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using ...
Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...
The Victoria Advocate26d
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma ...
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma By Myrio Therapeutics Jun 13 ...
KTLA25d
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma. News provided by.
KXAN25d
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of ... - KXAN Austin
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma. News provided by.